Background Male breast cancer (MBC) is rare. Given the paucity of randomized trials,
treatment is generally extrapolated from female breast cancer guidelines. Methods This is a …

Male breast cancer (MBC) is rare, accounting for less than 1% of all breast cancer but the
incidence has increased worldwide. Risk factors include increased longevity, obesity …

Male breast cancer is rare, accounting for 1% of all breast cancer diagnoses in the USA.
Because of its rarity, most major breast cancer trials have included only female patients. This …

Male breast cancer is rare, and experience of it in any single institution is limited. Our current
understanding regarding its biology, natural history, and treatment strategies has been …

Male breast cancer (MBC) is a rare condition that accounts for 0.1% of all male cancers. Our
current evidence base for treatment is derived from female breast cancer (FBC) patients …

Background Male breast cancer (MBC) is a rare disease accounting for approximately 1% of
all breast carcinomas. Presently treatment recommendations are derived from the standards …

Male breast cancer (MaBC) is a rare clinical entity, which makes up approximately 1% of all
breast cancers. However, the incidence of MaBC has been steadily increasing over the past …

Male breast cancer (MBC) accounts for approximately 1% of all breast cancers, limiting the
data characterizing clinicopathologic features and treatment outcomes in patients with MBC …

Male breast cancer (MBC) is a rare disease, accounting for 1% of all breast cancers.
Because of its rarity, it is treated similar to female breast cancer, although important …

Studies concerning adjuvant systemic therapy and prognosis in male breast carcinoma
(MBC) are limited. We aimed to evaluate outcome of the changing practices of adjuvant …